» Articles » PMID: 24727060

A New Adjuvant Delivery System 'cyclic Di-GMP/YSK05 Liposome' for Cancer Immunotherapy

Overview
Specialty Pharmacology
Date 2014 Apr 15
PMID 24727060
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclic dinucleotides are of importance in the field of microbiology and immunology. They function as second messengers and are thought to participate in the signal transduction of cytosolic DNA immune responses. One such dinucleotide, cyclic di-GMP (c-di-GMP), stimulates the immune system. It is thought that c-di-GMP is recognized by ATP dependent RNA helicase (DDX41) in the cytosol, forms a complex with the Stimulator of interferon genes protein (STING), triggers a signal via the tank binding kinase 1-interferon regulatory factor 3 (TBK1-IRF3) pathway and induces the production of type I interferons. Therefore c-di-GMP can be thought of as a new class of adjuvant. However, because c-di-GMP contains two phosphate groups, this prevents its use as an adjuvant because it cannot pass through the cell membrane, even though the target molecule of c-di-GMP is located in the cytoplasm. Our group has been developing a series of liposomal drug delivery systems and recently investigated YSK05 which is a synthetic, pH sensitive lipid that has a high fusogenicity. We utilized this lipid as a carrier to transport c-di-GMP into the cytosol to then use c-di-GMP as an adjuvant. Based on screening experiments, YSK05/POPE/cholesterol=40/25/35 was found to induce IFN-β in Raw264.7 cells. The induction of IFN-β from c-di-GMP liposomes was inhibited by adding BX795, a TBK1 inhibitor, indicating that the production of IFN-β caused the activation of the STING-TBK1 pathway. C-di-GMP liposomes also showed significantly higher levels of expression of CD80, CD86 and MHC class I. The c-di-GMP/YSK05 liposome facilitated antigen specific cytotoxic T cell activity and the inhibition of tumor growth in a mouse model. These findings indicate that c-di-GMP/YSK05 liposomes could be used, not only to transfer c-di-GMP to the cytosol and induce an innate immune system but also as a platform for investigating the mechanism of immune sensing with cyclic dinucleotides in vitro and in vivo.

Citing Articles

Low-Intensity Focused Ultrasound-Responsive Phase-Transitional Liposomes Loaded with STING Agonist Enhances Immune Activation for Breast Cancer Immunotherapy.

Hu C, Jiang Y, Chen Y, Wang Y, Wu Z, Zhang Q Cancers (Basel). 2024; 16(21).

PMID: 39518096 PMC: 11545222. DOI: 10.3390/cancers16213657.


Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses.

Zhang X, Shi H, Hendy D, Bachelder E, Ainslie K, Ross T mSphere. 2024; 9(7):e0016024.

PMID: 38920382 PMC: 11288037. DOI: 10.1128/msphere.00160-24.


Bis-2'-F-cGAMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines.

Yu J, Yu X, Sun X, Wang Q, Long S, Ren R Mol Ther. 2024; 32(6):1917-1933.

PMID: 38637990 PMC: 11184333. DOI: 10.1016/j.ymthe.2024.04.023.


Role of STING in the treatment of non-small cell lung cancer.

Tang W, Zhou W, Ji M, Yang X Cell Commun Signal. 2024; 22(1):202.

PMID: 38566036 PMC: 10986073. DOI: 10.1186/s12964-024-01586-x.


Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bCD27 memory-like NK cells.

Khalifa A, Nakamura T, Sato Y, Harashima H Exp Hematol Oncol. 2024; 13(1):36.

PMID: 38553761 PMC: 10981311. DOI: 10.1186/s40164-024-00502-w.